BCX17725 — Initial data
Late 2026
The company is dosing in Part 4 of this trial, which will enroll up to 12 patients for three months, and expects to report data from this part by the end of 2026.Source filing
BCRX biotech catalysts & pipeline
BIOCRYST PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
navenibart — Topline data
early 2027
Navenibart is in Phase 3 clinical development with top line data from the pivotal ALPHA-ORBIT trial expected in early 2027 and has the potential to be the leading injectable HAE treatment.Source filing
navenibart — Topline data
Q3 2027
The program remains on track to report top-line results from both doses in Q3 2027.Source filing
navenibart — NDA/BLA submission
Late 2027
The program remains on track to support regulatory filing in the US by the end of 2027.Source filing